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GLOSSARY 
Filamentous growth- refers to the presence of hyphae in a culture or sample 
Germ tube- newly evaginating hypha 
Hyphae- microscopic tube that contains multiple fungal cell units divided by septa; 
arises from a yeast cell 
Pseudohyphae- end-to-end aggregation of yeast cells which are very elongated; 
resemble true hyphae but have constrictions at septal junctions 
Septum- cross wall between the parent and daughter cell units 
Yeast cell- round unicellular yeast form; referred to as a blastospore in past literature 
but found not to he a spore 
Chlamydospore- large, thick-walled cell that is subtended from hyphae or 
pseudohyphae by a cell called a "suspensor cell" 
v 
ABBREVIATIONS 
ARF- ADP-ribosylation factor 
AVP ... Arg-vasopressin 
BPA- BODIPY phosphatidic acid 
BPC- BODIPY phosphatidylcholine 
BDG- BODIPY diacylglycerol 
CLA4- gene which encodes a serine/threonine kinase activity 
DAG- diacylglycerol 
DGK- diacylglycerol kinase 
DG kinase- diacylglycerol kinase 
ET -1- Endothelin-l 
LPA- lysophosphatidic acid 
PA- phosphatidic acid 
PAP- phosphatidic acid phosphohydrolase 
Pbu- phosphatidylbutanol 
PC- phosphatidylcholine 
PDGF - platelet-derived growth factor 
PIP2- phosphatidylinositol 4, 5-bisphosphate 
PI4P-5K- phosphoinositol 4-phosphate 5-kinase 
PKC- protein kinase C 
PLA2- phospholipase A2 
PLC- phospholipase C 
VI 
PLD- phospholipase D 
PLD1- phospholipase D isoform in Candida albicans 
YEP- yeast extract, peptone medium 




Phospholipase D (PLD) enzymes play significant roles in phospholipid metabolism, 
secretion, and lipid signal transduction. The yeast Candida albicans possesses a PLD 
activity that is designated PLDI. This enzyme has been implicated in the regulation of 
dimorphic transition. In vivo assays using sphinganine, propranolol, and staurosporine 
were used to test the importance of phosphatidic acid (PA) and diacylglycerol (DAG), 
two downstream products of PLDI activity. A concentration of 5 J.lM sphinganine was 
sufficient to decrease the appearance of germ tubes with no effect on culture doubling 
times. However, at higher concentrations sphinganine was inhibitory to cell growth. 
Propranolol concentrations up to 1 mM were able to inhibit germ tube formation without 
increasing doubling times. Increasing concentrations of propranolol (e.g. 2 mM) did 
inhibit yeast cell growth. Varying concentrations of staurosporine had no effect on either 
germ tube formation or cell growth. In vitro assays demonstrated a decrease in the 
conversion of PA to DAG with increasing amounts of propranolol. Since DAG kinase 
assays showed that DAG levels were not affected, in vivo, by the presence of propranolol, 
phosphatidic acid phosphohydrolase (PAP) activity was measured in the presence of 
propranolol. No significant change in PAPase function was observed. Wildtype. 
albicans, SC5314, showed numerous, invasive hyphae when plated on Spider 
medium, in contrast to a confirmed pldl~ mutant which showed no visible hyphae. DAG 
kinase assays comparing DAG levels between the wild type and mutant strain showed 
significantly higher levels in the null mutant. These results suggest that C. albicans may 
be compensating for a loss of PLD-derived DAG, possibly through up-regUlation of 
Vin 
phospholipase C (PLC). The enzymes monoacyl-glycerol-acyl-transferase (MAGAT) 
and inositol-phosphoryl ceramide synthase (IPC synthase) may participate in replacement 







Phospholipase D (PLD) is a signal transducing enzyme that has been shown to be 
involved in the regulation of cellular functions such as differentiation~ proliferation, and 
senescence (1). PLD has been shown to hydrolyze phosphatidylcholine to produce 
phosphatidic acid (PA) and choline (2, 3) PLD can also be involved in the transfer of a 
phosphatidate group to a primary alcohol to produce a phosphatidylalcohol (4). Isoforms 
of PLD have been found in mammals, plants, bacteria (2), and fungi (5, 6). 
PA has been implicated as an effector of such processes as secretion (7), DNA 
synthesis, and cell proliferation (8, 9). Phosphatidic acid can be converted to 
lysophosphatidic acid (LPA) by the enzyme PLA2 (3). It can also be broken down by PA 
phosphohydrolase to produce diacylglycerol (DAG) (10). DAG is known to be a second 
messenger that can activate some members of the protein kinase C family (11). 
It has been shown that inhibitors ofPKC partly or totally inhibit activation ofPLD in 
many cell types (12). However, there are also examples in \vhich inhibitors ofPKC do 
not inhibit PLD (13). These results indicate that both PKC-dependent and independent 
mechanisms are involved in the regulation ofPLD. Many substances that stimulate PLD 
also activate the breakdown ofPIP2 by phosphoinositide phospholipase C (PI~PLC). 
This breakdown results in the production of inositol trisphosphate and diacylglycerol. 
Diacylglycerol is responsible for activating PKC isozymes. These enzymes, which are 
Ca2+ sensitive, in tum activate PLD (14). Researchers have supported this process of 
regulation with genetic mutations or disruptions involving PI-PLC and overexpression of 
PI-PLC. For example, cells expressing mutated PDGF receptors showed a decrease in 
PI-PLC response to PDGF, leading to a loss of PLD response to PDGP (15). Cells from 
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mice in which the PI-PLCy gene had been disrupted exhibited a similar result of 
decreasing PLD response to PDGF (18, 22). Cells overexpressing PI-PLCy were shown 
to have increased PLD response to the growth factor (16). PLD response to PKC 
isoforms can either both dependent or independent of A TP. Studies using brain PLD 
have shown activation by PKCu that does not require ATP and is not inhibited by 
staurosporine (17). This suggests a phosphorylation-independent mechanism for this 
particular PLD stimulation (14). On the other hand, activation ofPLD by PMA in 
penneabilized human embryonic kidney cells, is inhibited by staurosporine, requires 
MgATP, and is blocked by certain PKC inhibitors (18). 
ADP-ribosylation factors (ARFs) have been shown to regulate certain isoforms of 
PLD. It has been shown that regulation ofPLD in membranes and permeabilized HL60 
cells by GTPyS require a cytosolic factor (19). This factor was later identified as ARF 1 
and ARF3 (20, 21). The presence of an ARF-regulated PLD in the cytosol of HL60 cells 
was also demonstrated (22). At present, ARF-regulated PLD activity has been found in 
nuclei (23, 24), Golgi, plasma membranes, (24-26) and cytosol (22, 24, 27). 
PLD regulation by small GTP binding proteins of the Rho family has also been 
demonstrated. This regulation was first shown in studies with neutrophils (28). This 
group demonstrated that PLD activation by GTPyS required both plasma membrane and 
cytosol fractions. The activation also required protein factors from both fractions (28). 
Activity that was specific for GTPyS showed properties of a small GTP binding protein. 
When a GDP dissociation inhibitor specific for the Rho family was added, PLD 
activation by GTPyS was inhibited (28, 29). These results show that the Rho family of 
small GTP binding proteins is involved in PLD activation. 
3 
PLD activation has also been shown to be regulated by protein tyrosine kinases. 
Tyrosine phosphorylation plays an important role in physiological functions such as cell 
metabolism, differentiation, and growth regulation (30). Receptor tyrosine kinases on the 
plasma membrane mediate signal transduction of certain growth factors such as PDGF 
(31). Endothelin-l (ET -1) and PDGF were both shown to stimulate PLD in smooth 
muscle cells (32, 33). However activation ofPLD by ET-l was shown to be sensitive to 
inhibitors ofPKC and tyrosine kinases (33), while studies with PDGF suggested a 
receptor-independent pathway for activation ofPLD (32). PLD activation by non-
receptor tyrosine kinases was also found using BALB/C 3T3 murine cells transformed 
with v-src (34). This stimulation ofPLD by oncogenes involves an increase in PKC and 
tyrosine kinase activity (35, 36). An increase in DAG levels has also been observed in v-
src transformed cells (37). However, in time courses fOf these experiments, the increase 
in DAG levels did not correspond to the amount of inositol phosphate accumulated (38). 
This discrepancy suggested the possibility ofDAG formation via breakdown of another 
phospholipid, such as phosphatidylcholine. The increase in DAG was shown to be due to 
PLD activation, which led to the hydrolysis ofPA by PA phosphohydrolase to produce 
DAG (34, 39). In addition, this PLD activation by v-sre was found to be PKC-
independent, since it was unaffected by the PKC inhibitor staufosporine (34). 
PLD ACTIVITY IN YEAST 
The first PLD activity in fungi was found in Saccharomyces cerevisiae and 
designed SP014 (yPLDl). The SP014 gene of S. cerevisiae encodes a PC-PLD that is 
capable of performing the transphosphotidylation reaction and has been shown to be 
regulated by carbon source (5). PC- specific PLDs can also promote the transfer of the 
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phosphatidyl group of PC to a primary alcohol to produce phosphatidylalcohol, which 
has been very useful in measurement ofPLD activity in mammalian systems (4). 
However, the transphosphatidylation reaction ofyPLDl is not as efficient as that of the 
mammalian enzymes (40). This may be due to the fact that phosphatidylethanol is also a 
substrate ofyPLDI and may be hydrolyzed upon production, making accurate 
measurements difficult (3). PLDI-deficient mutants cannot successfully complete 
meiosis and sporulation (41), and there is an absence ofPC-PLD activity in these cells 
(11, 43). A 400 amino acid region near the middle of the SPO 14 gene shows sequence 
similarity to a castor bean PLD (40). PLD activity has been found in membranes from 
bacteria (40) and insect cells (42) expressing the SP014 gene. 
PC-PLD activity has also been found in C. albicans, where it is referred to as 
PLD 1 * This is a membrane-associated PLD activity that can perfonn 
transphosphatidylation with alcohols, is increased during dimorphic transition, and is 
regulated by carbon sources (43). 
CANDIDA ALBICANS 
Candida albicans is a pathogenic yeast that has severe consequences in 
immunocompromised hosts, including patients with AIDS, those receiving 
immunosuppressive therapy as cancer treatment or after transplant operations, and those 
undergoing antibiotic therapy (44). It is the most common opportunistic fungal infection 
in high-risk hosts. Although candidiasis can be treated if diagnosed early, it can be fatal 
if not recognized (44). 
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Growth o/Candida in the Human Body 
Candida species that cause infection can be isolated throughout the animal 
kingdom. The major source of these yeast species in human disease is endogenous (45). 
The predominant areas of Candida colonization in humans are the mouth, gastrointestinal 
tract, vagina, and skin. Within the mouth, the tongue is the site of the largest yeast 
population, followed by the palate and the cheeks (46,47). However, in those individuals 
with denture prostheses, the yeast population is greatest on the area of denture fitting 
(46). Isolation of Candida species in fecal samples show very little difference between 
healthy and unhealthy individuals, and the concentrations found are typically very low 
(45). Yeast concentrations in the gut are relatively high, similar to those of the oral 
cavity. The literature varies widely as to precisely what parts of the gut have the highest 
concentrations of Candida, but isolates can be found in all parts of the gastrointestinal 
tract (45). C. albicans carriage frequency from the human vagina of "nonnal" 
individuals has been estimated at 22.30/0. However, the carriage frequency from patients 
with vaginitis was estimated at 31.8% (45). These carriage data are approximately a 
decade old, but are still useful to illustrate the areas that may be most susceptible to 
excess colonization and candidiasis. 
Predisposition to Candidiasis 
The phrase "compromised host" is typically used to describe someone that is 
susceptible to infection by a Candida species. This does not mean, however, that the host 
must have a severe predisposing factor such as immune deficiency. Natural, dietary, 
mechanical, and iatrogenic medical factors all contribute to an individual's vulnerability 
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to candidiasis (Figure 1.1) (45). Examples within these classifications include age, 
microbial infections, vitamin deficiencies, dentures, and antibiotics. 
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CLASSIFICA TION OF EXPLANA TION 
DISPOSING FACTOR 
Natural Factors l. Infectious, congenital, idiopathic, or other 
diseases 
2. Digressions from normal physiological status 
Dietary Factors 1. Excess or deficiency of food that may alter 
normal microbial flora 
Mechanical Factors 1. Trauma 
2. Occlusion or maceration of tissues 
Iatrogenic Medical 1. Drug treatments that alter nonnal body flora or 
host defenses 
2. Surgical procedures or prostheses 
Table 1.1: Classification of Factors that Predispose Humans to 
Candidiasis (Adapted from reference 45). 
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C. albicans Morphology 
C. albicans can exist in two major morphologies. One is the budding yeast cell, and 
the other is the filamentous or hypha! form. This hypha! fonn can appear either as true 
hyphae with no segmentation from the parent cell, or as pseudohyphae that have 
constrictions at the septal junctions (Figure 1.1) (45). Candida cells can be induced to 
undergo morphological changes by various environmental factors including temperature, 
pH, and nutritional status. Both the yeast and hyphal forms have been associated with 
infection. However, hyphal cells are the predominant fonn in most infections. Hyphae 
have enhanced ability to invade host tissue and disseminate an infection, and hyphal 
filaments can more effectively destroy phagocytic cells from the inside. 
There seems to be some mechanical advantage to the ability to switch morphologies. 
This advantage may be related to the success of Candida as a fungal pathogen. For this 
reason, much work has been directed toward the regulation of morphogenesis, and some 
of the proteins and enzymes involved have been indentified (Figure 1.2). These 
components have been identified as homologues of the MAP kinase pathway, largely by 
their ability to complement mating defects in S. cerevisiae mutants (48-52). Defective 
hyphal growth on solid medium results from a single disruption in any of these genes. 
However, these mutants still exhibit characteristic induction of hyphae by human serum 
(48-50, 52). A cphl/ejgl double mutant, unlike the single mutants, was unable to fonn 
hyphae even in the presence of human serum. This double mutant was also shown to be 
avirulent in a mouse candidiasis model (53). This same sort of altered virulence can be 
seen with mutations in the CLA4 gene, which encodes a Ste20-related kinase. The cla4~ 
mutants are incapable of forming hyphae and exhibit no virulence in mouse models (54). 
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Negative regulators of Candida morphogenesis have also been identified. Mutations 
involving either MAP kinase phosphatase or the transcriptional corepressor Tupl 
enhance the formation of hyphae (54-56). Identification of these positive and negative 
regulators of morphogenesis, and the connection being made between a decreased hyphal 
formation and avirulence, continues to strengthen the argument that the morphogenic 
switch is needed for infection. 
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A) B) 
Figure 1.1: Morphogenesis of Candida albicans. A) The process of 
budding in C. albicans. The mother yeast cell produces a new cell growth at 
a site near one of the cell poles. The new cell growth or bud will 
beseparated from the mother cell by a septum, after mitosis. At this point 
both cells are independent and can undergo the budding process once again. 
B) Hyphal formation in C. albicans. The outgrowth of new cellular 
material appears. This first appearance is referred to as the germ tube. As 
the germ tube lengthens, septa are laid down behind the extending tip, and 
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~ Activated Transcription 
Figurel.2: Morphogenesis Pathway in C albicans. 
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PROPRANOLOL AS AN INHIBITOR OF PA PHOSPHOHYDROLASE 
A significant tool in this study was propranolol, which is an inhibitor of certain 
forms ofPA phosphohydrolase (PAP), the enzyme responsible for the conversion of 
phosphatidic acid to diacylglyceroL At moderate concentrations (250J.lM) of propranolol, 
this inhibition of PAP occurs without affecting PLC and PLD activities in human 
neutrophils (57)). In mammalian systems, propranolol is used as a t3-adrenergic receptor 
blocking agent, to reduce the action of adrenaline in the body (58). The use of 
propranolol in PLD studies has been well established in literature concerning mammalian 
systems. For example, Naro et al. exposed the rat skeletal muscle cell line L6 to Arg-
vasopressin (A VP). A VP is a neurohypophyseal hormone that induces myogenic 
differentiation, which leads to the expression of myogenic regulatory factors. In studying 
this mechanism of my ogene sis, propranolol was used to establish the relevance of 1,2-80-
diacylglycerol produced by PLD activity, independent ofPLC activity, in L6 cells (59). 
Recently, propranolol was used to demonstrate the involvement of a PLO-mediated 
signaling mechanism in the angiotensin (Ang) II-induced growth of vascular smooth 
muscle cells (VSMC). Ang II is a peptide that acts as both a vasoconstrictor and a 
mitogen in VSMC. It mediates its effects through the activation of various signal 
transduction cascades, such as the activation ofPLC (60) and protein tyrosine kinases 
(61). VSMC cultured from rat aorta were incubated with propranolol (0- 10,000 nM 
concentrations) both 5 minutes prior to and during stimulation with Ang II. A dose-
dependent decrease in DNA synthesis was shown with 10 f.lM being sufficient to block 
the VSMC growth (62). 
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CHAPTER 2 
ESTABLISHMENT OF A ROLE FOR PLDt IN DIMORPHISM IN C. ALBICANS 
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The switch from yeast-form cells to hyphal cells in C. albicans has been 
associated with the establishment of infection (63). PLDI has been shown to playa role 
in this transition (43). However, little is known about the specific roles of this enzyme in 
the Candida morphogenesis pathway_ Therefore, PLD! as well as two of its downstream 
products, DAG and PA, were investigated. We tested the ability of Candida to switch 
morphology in the presence of several pharmacological agents. These agents were 
chosen based on their effects on the activity of enzymes that might playa role in 
regulating this switch. Propranolol was used because of its ability to block the 
conversion of phosphatidate to DAG by inhibiting phosphatidate phosphohydrolase. 
Sphinganine was used because of its action as a phospholipase D inhibitor (6). We also 
assayed cells for PLD 1 activity when presented with these same agents to measure the 
effect on downstream products of PLD 1. A final pharmacological agent, staurosporine, 
was used to detennine whether PLDl-derived DAG was acting through PKC. 
MATERIALS AND METHODS 
Assay of Dimorphism Induction 
A 2 m1 YPD culture was inoculated with C. albicans strain 28367 (wild type) and 
grown 16-18 hours at 30oe. The culture was then adjusted to 1 x 1 06 cells/ml in YPD 
broth. This suspension was divided into culture tubes. The appropriate experimental 
agents were added (Table 2.1). Each assay set contained a cell-only control. A parallel 
assay set with the same parameters contained fetal bovine serum (FBS) at a final 
concentration of 20% (v/v). All tubes were incubated at 39°C in a shaking water bath for 
2 hours. At the end of 2 hours, all samples were removed and 0.10 volume of 
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fonnaldehyde was added to each tube. Cells were counted, and the percentage of hypha! 
cells was determined. 
Effect of Pharmacoloeical Agents on Growth 
Growth curves were perfonned using each agent shown in Table 2. A 2 m1 YPD 
culture was inoculated with C. albicans strain 28367 (wild type) and grown for 16-18 
hours at 30°C. Fifty microliters of this overnight culture were used to inoculate a 10ml 
flask of YPD to an OD of approximately 0.150 to 0.200. This step was repeated until 
enough flasks had been set up to accommodate a zero control and each concentration of 
the experimental agent being examined. Absorbance measurements were taken at 600nm 
using a spectrophotometer (Milton Roy, Spectronic 601). Readings were recorded every 
hour until the control cell culture had reached log phase growth. Absorbance was then 
determined and doubling times calculated. 
AGENT FINAL 
CONCENTRATION 
Propranolol 0.5, 1.0, 1.5, 2.0 mM 
Sphinganine 5.0, 10.0, 25.0 JlM 
Staurosporine 1.0, 2.0, 5.0, 10.0 nM 
Table 2.1: Pharmacological Agents and Concentrations. 
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Biochemical Assay of PLDI Activity 
A 10 ml YPD culture was inoculated with C. albicans strain 28367 (wildtype) and 
incubated 16-18 hours at 30°C. Cells were harvested, washed in sterile distilled water, 
and resuspended in one volume of lysis buffer (20mM Hepes, pH7.5, 150mM NaCI, 
2mM EDTA, ImM DTT, lOOmM f)-glycerophosphate, 5JJ,g/mlleupeptin, IJlg/ml 
pepstatin, O.lmM PMSF). One volume of glass beads was added, and the cell suspension 
was mixed lOx 30 seconds using a vortex mixer. The suspension was centrifuged at 
12,OOOxg for 15 seconds to pellet beads and cell debris. The supernatant (whole cell 
extract) was collected, and protein concentration determined using the Bradford assay. 
Five micrograms of protein were used in each reaction. A fluorescent analog of 
glycerophosphocholine, BODIPY-PC (Molecular Probes), was used as the substrate. 
Final reactions contained 5 ug protein, lysis, resuspension (O.37SmM NP-40, 350mM 
NaCI, 50mM Repes, pH7.5), and 5x reaction buffer (35mM HEPES, pH7.5, ImM 
EDTA, 25mM EGTA, 3mM DTT, 5% butanol) in a final volume of 25 ilL These assays 
examined the effects of the previously mentioned inhibitory agents (Table 2.1). 
Experimental agents were added immediately before addition of cell extracts. All 
samples were assayed in duplicate. Reactions were incubated for 30 minutes at 30°C. 
After 30 minutes, samples were placed on ice to stop the reaction. Five microliters of 
each reaction were spotted on silica gel 60 plates and developed with methyl acetate/l-
propanol/chloroform/methanoI/O.25% Kelt acetic acid (100:100:100:40:36:2). A 
Fluorimager (Molecular Dynamics) was used for quantitation. Control and experimental 
reactions were spotted on the same plate, and experimental products were quantitated 
relative to the fluorescence of the control, which contained only lysis buffer plus reaction 
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mixture with no extract. Each experiment was repeated at least three times with 
independent extracts. 
Biochemical Assay For Phosphatidic Acid Phosphohydrolase Activity 
This assay was used to detect and quantitate PAPase activity in the presence of 
propranolol. The protocol used was the same as for the PLD 1 activity mentioned 
previously in this chapter; however, the BODIPY -PC substrate was replaced with (3-
BODIPY PA (Molecular Probes). Within each experiment, increasing BPA 
concentrations were used with a fixed propranolol concentration~ The data collected was 
analyzed using a Lineweaver-Burk plot to find Michaelis constant (KM) and the rate of 
the eatal ytic process (kcat). 
Quantitation of DAG 
Preparation of cells: 
A 100 ml YPD culture was inoculated with C~ albicans strain 28367 (wildtype) 
and incubated 16-18 hours at 30°C. Propranolol was then added to the culture to a final 
concentration of 2 mM. Ten milliliter samples were taken at 0, 15, 30, 60, and 120 
minutes. Cells were harvested by centrifugation at 600 x g for 5 minutes immediately 
after each sample was taken and stored at -70°C until the time course was complete. 
Extraction of lipids by Bligh and Dyer method: 
Once the time course was completed, a lipid extraction was performed on samples 
obtained at each time point. Methanol was added in a 50: 1 ratio (mg pelletml methanol), 
and glass beads were added to each sample in a 100:7 ratio (mg pellet:g glass beads). 
Cells were broken by milling with a vortex mixer for two 30-second pulses with 1 minute 
at 4°C between pulses. Chloroform was added to a final ratio of 2: 1 
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chloroforrn:methanol and stirred for 2 hours at room temperature. The extracts were 
filtered through Whatman #1 filter paper to remove glass beads and cell debris. Each 
extract was transferred to a glass screw cap tube and washed with 0.2 volume 0.9% NaCI 
to remove water-soluble contaminants. The aqueous phase was removed, and the organic 
phase was stored at 4°C under nitrogen vapor. 
Phosphate Assay: 
Lipid samples were normalized with respect to total phospholipid concentration. 
Phospholipids were quantified by measuring the phosphate content of the samples. 
Phosphate standards were prepared using a ImM NaH2P04 stock. Lipid samples were 
prepared using 200 ul of each sample; 100 ul of ashing buffer [10 g Mg (N03)2/100 ml 
EtOH] were added to all standards and lipids. The BtOH and chloroform were 
evaporated from the samples by incubation at 80°C for 20 minutes. Samples were then 
heated with a Bunsen burner until brown vapors ceased to be released from the reaction. 
Hel (0.5 N, 0.3 ml) was added to each tube and samples were boiled for 15 minutes. 
Ammonium molybdate (0.6 m! of 0.42%, w/v in 1 N H2S04) and ascorbic acid (0.1 ml of 
10%, w/v) were then added. Samples were mixed vigorously and incubated at 45°C for 
30 minutes. Absorbance readings were then taken at 820 nrn. 
DGKAssay: 
Lipid samples were dried in glass screw cap tubes in two different amounts, 100 11-1 
(A) and 250 Jll (B), for each time point. Samples were dried by placing the tubes in a 
30°C heat block in a vacuum desiccator. Lipids were resuspended in 20 III 7.5% B-
octylglucoside (~-OG) with mixing. Seventy microliters of reaction buffer, which 
consisted of 50 Jll 2xBuffer, 3 mM DTT, 0.44 JlI DGK-containing membrane 
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prpeparation (3.8 Ilg/JlI), and 19.36 JlI dilution buffer, were added to each tube and 
mixed. The 2xBuffer contained 400 mM imidazole pH 6.6, 240 mM Liel, 25 mM MgCI2 , 
200 mM EGTA pH 6.6, and 37.5 m1 sterile distilled H20. Dilution buffer consisted of 40 
mM imidazole pH 6.6,50 J.LM EDTA, and 39 m1 sterile distilled H20. The reaction was 
initiated by adding 10 J.tl of2 mM [y_32p] ATP (4 /lei/ sample) to each tube and 
incubating at room temperature for 30 minutes. Reactions were terminated by the 
addition of 3 ml of chlorofonn: methanol (1: 2) and mixing. Samples were centrifuged at 
3,000 rpm for 5 minutes to separate phases. The aqueous phase was removed, and the 
organic phase was collected and dried in a 30°C heat block under vacuum. Samples were 
resuspended in 50 J..lI chloroform; half of each sample was spotted on a TLC plate 
(Whatman Silica 60A). Spots were air-dried, and the plate was developed in 
chloroform: acetone: methanol: acetic acid:water (10:4:3:2:1). The plate was air- dried and 
exposed to film overnight. DAG spots for each lipid sample were scraped from the plate 
and counted using a 1211 Rackbeta scintillation counter (LBK-Wallac). The DAG 
amounts (cpm) were then normalized to total phospholipids, which had been determined 
using the phosphate assay. The results of this normalization were then used the 




Assay of Dimorphism Induction 
Sphinganine: 
Sphingolipids, particularly sphinganine, have been shown to inhibit mammalian 
PLDs. Consequently, the effect of sphinganine on dimol])hic transition was measured. 
In the morphology assays, sphinganine completely eliminated genn tube fonnation at 
25 J.lM (Figure 2.1). A concentration of 5 uM was sufficient to show a significant 
reduction of 150/0 in the efficiency of morphogenesis. A disruption in cell proliferation 
would be one way that germ tube fonnation could be reduced, since a germ tube arises 
through extension of the mother cell rather than by remodeling of the yeast cell. In 
determining whether or not this reduction in germ tubes was caused by inhibition of cell 
proliferation, we found that 5 11M sphinganine had no effect on doubling times (Table 
2.2). However, higher concentrations of sphinganine inhibited on growth. This result 
supports the hypothesis that PLD 1 is involved in morphogenesis. 
Propranolol: 
Propranolol has been used to distinguish the effect ofPA from the effect ofDAG 
derived from PA. Propranolol has been demonstrated to inhibit the conversion ofPA to 
DAG, presumably by inhibition of PAP. Increasing propranolol concentrations resulted 
in increased inhibition of germ tube formation. Two millimolar propranolol completely 
blocked the formation of hyphae (Figure 2.2). Growth curves in the presence of 
propranolol suggested that the inhibition of germ tube formation was not due to a block 
in cell proliferation, since concentrations that were sufficient to reduce morphogenesis 
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(e.g., 0.5 mM) had no;effect on cell doubling times (Table 2.2). However, higher 
concentrations of propranolol (e.g., 2 mM) did inhibit yeast growth. 
Temperature shift, alone, induces one pathway which leads to morphogenesis. 
However, a temperature shift plus bovine calf serum induces multiple parallel pathways 
leading to morphogenesis. When serum was introduced, in order to test the significance 
of propranolol's inhibitory effect, there was a small increase in the number of genn tubes 
at the OmM concentration. However, serum appeared to have no effect on germ tube 
formation in the presence of propranolol. 
Staurosporine: 
Staurosporine is known to be an inhibitor of protein kinase C and other protein 
kinases in mammalian systems. For this reason, it was used to determine if protein 
phosphorylation was required for hyphae fonnation. Staurosporine had no effect on 
dimorphic transition, with the negative control showing the same genn tube percentages 
as the culture with 25 nM staurosporine (Figure 2.3). Staurosporine was also shown to 
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Figure 2.1: Effects of Sphinganine on Candida Morphogenesis. Cells 
were induced to undergo morphogenesis in the presence of the indicated 
concentrations of sphinganine. The percentage of cells with germ tubes was 
calculated. Each point represents the mean +/-standard error for 3 
independent experiments with duplicate samples within each experiment. 
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Figure 2.2: Effects of Propranolol on Candida Morphogenesis. Cells 
were induced to undergo morphogenesis in the presence of the indicated 
concentrations of propranolol. The percentage of cells with germ tubes was 
calculated .. Each point represents the mean +/-standard error for 4 
independent experiments with duplicate samples within each experiment. 
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Figure 2.3: Effects of Staurosporine on Candida Morphogenesis. Cells 
were induced to undergo morphogenesis in the presence of the indicated 
concentrations of staurosporine. The percentage of cells with germ tubes 
was calculated. Each point represents the mean +/-standard error for 3 























1.05 +/- 0.115 
1.05 +/- 0.126 
1.60 +/- 0.100 
No Growth 
1.21 +/- 0.010 
1.08 +/- 0.088 
1.15 +/- 0.044 
1 .22 +/- 0.060 
No Growth 
No Growth 
1.08 +/- 0.060 
1.02 +/- 0.054 
1.004 +/- 0.067 
1.00 +/- 0.017 
0.97 +/- 0.074 
Table 2.2: Effects of Pharmacological Agents on Population Doubling 
Times. Data are shown as an average of 4 separate experiments +/- standard 
error of the mean. 
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Biochemical Assay of PLDI Activity 
The results obtained in vivo suggested that propranolol might inhibit the conversion 
of PLDl-derived PA to DAG. Figure 2.4 illustrates the effects of propranolol on the 
conversion of PA to DAG in vitro. The in vitro assays used BODIPY-PC as the 
substrate. In samples containing ImM propranolol, PA amounts were 53.6% higher than 
in controls. In addition, the amount of DG in the 1 mM samples was 28.6% less than in 
samples lacking propranolol. P-values in both cases were less than 0.005, indicating 
statistical significance. Propranolol concentrations of 5 mM inhibited both DG and P A 
production. However, this concentration was concluded to be toxic to the cells, based on 
growth assays (Table 2.2). The data suggest that PLDl-derived DAG may be required 
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Figure 2.4: Propranolol Inhibits CaPLDl Activity. The TLC plate scan 
(left) shows CaPLDI activity in response to propranolol. The data 
quantitated in the right panel are based on the mean +/- standard error of 6 
independent experiments. 
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Dg Kinase Assays 
DG kinase assays were used to determine whether propranolol inhibited the 
formation of DAG in vivo. The data showed that the amount of DAG present after 120 
minutes of incubation with 2 mM propranolol was not significantly different from that of 
untreated cells (Figure 2.5). This result is not consistent with the 28.6% decrease in DAG 
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2IllM Propranolol 
Figure 2.5: DAG Levels In Vivo Show No Change in Response to 
Propranolol. Lipid extracts from cell cultures were exposed to 2mM 
propranolol for 2 hours. DAG levels were assayed using a DG kinase assay, 
as described in the text. Each point represents the mean +/- standard error 
for 4 independent experiments with duplicate samples within each 
experiment. 
30 
Biochemical Assay for Phosphatidic Acid Phosphohydrolase Activit}: 
A PAP assay was designed using BPA as the substrate. Time course assays for 
PAP activity using 50Jl,M BPA were perfonned, prior to the BPNpropranolol 
experiments, to ensure that the experiments were within a linear range of kinetics (Figure 
2.6). Experiments using propranolol showed no inhibition at any of the concentrations 
used. Even at a concentration of ImM, which was sufficient to block the conversion of 
PA to DAG in assays for PLD activity, no significant change in PAP function was 





~ ... .... 
~ 
OJ'OOl ... 
c.J 7500000 < 
~ 
~ .... ... 







Figure 2.6: Time Course of BP A Hydrolysis. Time course assays for 
PAP activity were performed to establish linear kinetics. A Fluorimager 
(Molecular Dynamics) was used to measure fluorescence. Experimental 
fluorescence was calculated relative to that of the control sample of 50llM 
BPA at 0 minutes. Each point represents the mean +/- standard error for 4 
independent experiments. 
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Figure 2.7: Effects of Propranolol on PA Phosphohydrolase Activity. 
Experiments were performed in which increasing concentrations of BP A and 
fixed concentrations of propranolol were incubated with yeast extracts, 
within each separate assay. The product produced from BPA hydrolysis was 
quantitated. Results were calculated from 4 independent experiments +/-
standard error of the mean. 
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CONCLUSION 
Wildtype strain 28367 showed a dose-dependent inhibition of germ tube formation 
when exposed to sphinganine, suggesting that PLD! may playa role in the cell 
morphology switch. This observation is strengthened by that fact that sphinganine did 
not affect cell proliferation at a concentration that was effective in inhibiting germ tube 
formation. A dose-dependent inhibition was seen with propranolol in morphogenesis 
assays (Figure 2.2), without a reduction in cell proliferation (Table 2.2). One would 
expect a similar pattern of results for sphinganine and propranolol, since both potentially 
affect the generation ofDAG, one by blocking phospholipase Dl activity and the other 
by blocking phosphatidate phosphohydrolase. The fact that staurosporine showed no 
effect on germ tube fonnation suggests a PKC-independent function for DAG. 
The effects of propranolol on DAG and PA levels observed using the PLD assays 
suggest that propranolol is inhibiting the enzyme phosphatidate phosphohydrolase (PAP). 
In vitro assays demonstrated a decrease in DAG, which supports the idea that DAG 
derived from PLDI-produced PA is playing a role in morphogenesis. However~ in 
testing the effect of propranolol in vivo, using DAG kinase assays, it was confirmed that 
there was no significant decrease in DAG concentration in strain 28367 at 2 mM 
concentrations of propranolol (Figure 2.5). These data suggest a potential for the cell to 
compensate for the decrease in the production of DAG by PLD 1. Such compensation 
may occur by upregulation of PLCI activity or inhibition of the CDP-choline pathway_ 
Compensation could also occur through the use of the enzyme mon-acyl-glycerol-acyl 
transferase (64) or inositol-phosphoryl ceramide synthase (65). AdditionallYt in vivo data 
may also point to an alternative mechanism in which propranolol does not inhibit PAP. 
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This idea is supported by the in vitro assays performed using a fluorescent-labeled P A 
(BPA) to measure PAP activity. With these assays, it was shown that increasing 
concentrations of propranolol had limited inhibitory effect on P A phosphohydrolase 
activity (Figure 2~7). Alternatively, the lack of inhibition in the assays using BPA as the 
substrate may be due to the location of the BODIPY group. The BODIPY group of BPC, 
which is the substrate used for PLD activity assays, is located on Carbon 1. In contrast, 
the BODIPY group of BPA is located on Carbon 2 (Figure 2.8). The Carbon 2 location 
could block the binding of propranolol to the P A molecule6 Furthermore, the high 
concentrations of propranolol needed to produce an effect also argues for a different 
mechanism. Inhibition of PLD activity in yeast is seen in the millimolar range (5), while 
in mammalian systems inhibition is seen in the micromolar range. Finally, it has been 
demonstrated that propranolol binds directly to acidic phospholipids such as P A and 
phosphatidylserine (66). Thus, propranolol may act by directly binding to PA, 
sequestering the P A from PAP and other downstream targets. 
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Figure 2.8: Structures of BODIPY-Labeled Substrates Used in 
Fluorescence Assays. The BODIPY group ofBPC is located on Carbon 1, 
unlike the BODIPY group of BPA, which is located on Carbon 2. In the 
BPC structure, Rl represents an undecyl group, and R2 represents a decanoyl 




THE PHENOTYPE OF A C. ALBlCANS PLDl MUTANT (Pldlill) 
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In order to more effectively examine the physiological role of PLD 1, a C. albicans 
PLDI mutant (Pldli\I) was constructed by our coIIaborator, Dr. Bernhard Rube of the 
Robert Koch Institute, Berlin. This mutant was used in our lab to analyze the phenotypes 
of a PLD 1 deficient C. albicans strain in order to establish a phenotype. PLO 1 assays 
were performed on the mutant (Pldl~l) and wildtype control (SC5314) to confirm the 
absence ofPLD1 activity in the mutant. Plate assays with various types of media were 
then used to establish a phenotype of the knockout. The media used were selected based 
on their ability to promote hyphae formation by wildtype cells at 37°C. 
MATERIALS AND METHODS 
Biochemical Assay of PLDI Activit! 
Assays were performed as described in Chapter 2. The assays were performed with 
extracts from strain SC5314 (wildtype) andpldl~l (mutant). 
Plate Assays to Examine Morphogenesis 
A variety of solid media (Table 3.1) were inoculated with both wildtype (SC5314) 
and mutant (Pldl~l) and incubated at 37°. Colonies were observed after 1 and 3 days. 
Colonies were photographed using a Zeiss MicroCam with 331 Polaroid film. 
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SOLID MEDIA DESCRIPTION 
Corn Meal (2% Low nutrient medium; promotes chlamydospores 
Tween) 
Lee's Synthetic Minimal medium with amino acids; promotes hyphae 
Saboraud Dextrose Glucose medium sometimes used for strain storage 
Spider (Mannitol) Mannitol as the carbon source; promotes hyphae 
Spider (Glucose) Glucose as carbon source 
YPD (Mannitol) Strain storage medium in which mannitol replaces 
glucose 
YPD (Glucose)- Glucose medium used for daily storage; promotes 
Control yeast cells 
Table 3.1: Media Used in Plate Assays. Each medium presents the cells 
with unique conditions that can alter morphology. 
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DG Kinase Assays 
Assays were performed as described in Chapter 2, using strain SC5314 (wildtype) 
andpldl~l (mutant). 
Measurements of Cell Growth in the Presence of Primary V s Secondary Carbon 
Sources 
YEP cultures, containing either mannitol or glucose as the carbon source, were 
inoculated with SC5314 andpldl~l. All tubes were be incubated for 16-18 hours at 
30°C. All cultures were then diluted to an OD of 0.150-0.200 and returned to the 30°C 
incubator. The absorbancy at 600 nm was measured hourly for each sample. Once log 
phase growth was reached, the experiment was terminated, and the absorbancies plotted 
against time to calculate a growth rate for each sample.. This experiment was repeated 
three times with independent overnight cultures. 
RESULTS 
Biochemical Assay of PLDI Activity 
To confirm that the pldl~l mutant lacked PLDI activity, the isogenic wildtype and 
mutant strains were assayed for PLDI activity in vitro. The wildtype strain sample 
contained all of the products indicative ofPLDl activity using this assay method: 
phosphatidic acid (PA), phosphatidylbutanol (PBu), and diacylglycerol (DAG). 
However, the mutant showed an absence of all of these products (67). These results 
showed a lack of PC-specific PLD activity, thereby confinning that C. albicans expresses 
a single PLD with this enzymatic activity. 
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Plate Assays to Examine Morphology 
Mutant cells plated on Spider medium at 37°C for 3 days showed no visible hyphae 
using microscopic observation at 40x (Figure 3.1). Wild type cells on Spider medium 
showed numerous invasive hyphae. Data with the pldlAl mutant established a decrease 
in morphogenesis on various types of media with the exception of Com Meal Agar (25 
Tween) and Lee's Synthetic medium (Table 3.2). 
The results obtained with the YPD control plates compared to the Spider medium 
plates prompted us to test the possibility that morphogenesis was regulated by a factor 
derived from the carbon source. The most distinct difference between Spider and YPD 
medium is the carbon source used. Glucose, which is the standard carhon source in YPD, 
is a rich six-carbon sugar that the cells can utilize readily. Mannitol, another six-carbon 
sugar, is used in Spider medium and is known to be a poor source of carbon for these 
cells. Spider medium plates in which glucose was substituted for mannitol yielded results 
similar to those of YPD for both wildtype and mutant. 
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SOLID MEDIA SC5314 (3 days) at 40x LlPLD14-3-2 (3 days) 
(at 37°C) Magnitude at 40x magnitude 
Corn Meal Agar Long hyphae with many Long hyphae with 
1(20/0 Tween) lateral buds many lateral buds 
Lee's Synthetic Hyphal formation Hyphal formation; 
wrinkled colonies 
Saboraud No visible hyphae No visible hyphae 
Dextrose 
Spider (Mannitol) Extensive t invasive hyphae No visible hyphae 
Spider (Glucose) No visible hyphae No visible hyphae 
YPD (Mannitol) Visible hyphae No visible hyphae 
YPD (Glucose)- Yeast cells; no hyphal Yeast cells; no hyphal 
Control formation formation 
Table 3.2: SC5314 and LlPLD 14-3-2 Morphologies on Different Media. 
Various media were selected based on their effects on morphology 
(see Table 3.1). 
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Figure 3.1: Wildtype (left) and Mutant (right) Colonies on Spider 
Media. A complete absence of extended hyphae was observed with the pld! 
mutant on Spider medium. Photographs were taken with x40 magnification. 
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Quantitation ofDAG 
It was anticipated that the pldl~l mutant would have lower DAG concentrations 
than the wildtype; however, DG kinase assays showed significantly higher DAG levels 
in the mutant (Figure 3.2). An ANOVA analysis calculated a p-value of 0.0462. This 
result suggests either that the cell can adapt to the loss of PLD 1 activity and maintain its 
pool ofDAG, or that PLDI is not a major source ofDAG. 
Measurements of Cell Growth in the Presence of Primary Vs Secondary Carbon 
Sources 
A lower growth rate was expected for pldllll cells as compared to wildtype when 
mannitol was used as the carbon source. This hypothesis was based on the fact that the 
use of a secondary carbon source (mannitol) in the plate assays resulted in increased 
hyphal formation (Figure 3.2). We hypothesized that cells may be using hyphal 
fonnation as a foraging mechanism when given mannitol. However, no difference in 








Figure 3.2: In Vivo DAG levels of SC5314 and pldl!11. Lipid extracts 
were assayed for DAG content using a DG kinase assay. Shown is the 
average of 4 separate experiments +/- the standard error of the mean. 
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CONCLUSION 
Initial plate assays established a distinct phenotype for the pldl i11 mutant on solid 
Spider medium. The mutant showed a complete absence of visible hyphae, in contrast to 
the wild type which showed extensive hyphae (Figure 3.1). These observations 
suggested that, as hypothesized, a product downstream ofPLDl is required for 
morphogenesis. To investigate whether or not this product of interest was DAG, DG 
kinase assays were performed on both the wild type and the mutant to compare in vivo 
DAG levels. These assays revealed a statistically significant difference in DAG levels 
between the two strains, with higher levels in the mutant samples. This could suggest 
that the mutant may be compensating for its loss of PLD I-derived DAG by using PLC-
derived DAG. This is presently being investigated in the lab, where preliminary data 
show that the mutant has increased PLC activity compared to the wild type. 
Compensation by PLC-derived DAG could occur based on the fact that the experiments 
discussed were carried out no longer than two hours, and it has been shown that PtdIns-
PLC activity contributes to the initial rapid phase of A VP-dependent DAG in a rat 
skeletal muscle cell line L6 (59). Naro et al. showed that PC-PLD activity was entirely 
responsible for sustained DAG levels which were required for the differentiation ofL6 
myoblasts into multinucleated fibers (59). Fungi may also transfer phosphoryl-inositol 
from phosphatidyl inositol (PI) to phytoceramide to form inositol-phosphoryl ceramide 
through the use of the enzyme IPC synthase. This reaction is accompanied by the release 
ofDAG (65). A final path which may be used to compensate for the loss ofPLD-derived 
DAG is by the conversion ofmonoacyl-glycerol-3-phosphate to PA by the enzyme 
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monoacyI-glycerol-acyl-transferase. The PA that is produced can then be 





The objective of this research was to establish a role for the enzyme PLDI in C. 
albicans~ specifically with regard to its involvement in morphogenesis. The results of this 
study are consistent with the hypothesis that a lack ofPLDl activity results in reduced 
ability to form hyphae. Therefore, loss ofPLDl activity potentially results in a less 
virulent pathogen. However, the results were not sufficient to establish a precise location 
for PLDI in the morphogenesis pathway, or to pinpoint which downstream products of 
PLDI (e.g., PA or DAG) are required for the yeast-to-hyphae switch. 
The experiments utlizing propranolol seemed to suggest the importance ofDAG in 
the morphological switch. The mechanism by which propranolol is presumed to act is by 
inhibition ofPA phosphohydrolase. This mechanism was tested using in vitro 
fluorescence assays with BODIPY-PA as the substrate. Interestingly, no inhibition was 
found with increasing concentrations of propranolol using this assay. One possible reason 
for the lack of inhibition is the structure of the substrate used in this assay. The 1-
BODIPY- PC is cleaved to I-BODIPY-PA by PLDI, and I-BODIPY-PA is rapidly 
dephosphorylated by PAP (Figure 2.8). In the PAP assays for propranolol inhibition, 2-
BODIPY-PA was used as a substrate (Figure 2.8). This form ofPA may not be a 
substrate for the propranolol-sensitive PAP. This is supported by Figure 2.4 which 
illustrates the dephosphorylation of I-BODIPY-PA to produce DAG. 
Another point of interest is that derived from the comparison of in vitro propranolol 
fluorescence assay data with that of the in vivo DAG quantitation experiments in the 
presence of propranolol. The decrease in DAG shown using the in vitro biochemical 
assays (Figure 2.4) was not seen with in vivo assays, which demonstrated no significant 
decrease in DAG levels in the 28367 wildtype in the presence of 2 mM propranolol. This 
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could be due to the possible use ofPLCl-derived DAG by the cells to compensate for the 
loss ofDAG produced through PLDI activity. This idea was shown to be the case with 
AVP-stimulated L6 cells in the presence of propranolol, where enhanced PA 
accumulation increased PLC activity (59). Compensation may also be due to the enzyme 
inositol-phosphoryl ceramide synthase (64) or mono-acyl-glycerol-acyl transferase (65). 
The data also suggests that loss ofPA, rather than insufficient DAG, may be responsible 
for the inhibition of morphogenesis. Data from our laboratory (Desrosier and Dolan, in 
preparation) show that the fluorescence of propranolol is quenched by PA in a 
concentration-dependent manner, suggesting that propranolol binds directly to the PA 
molecule. 
It can be concluded that a lack ofPLD1 activity has an adverse effect on hyphal 
formation and produces a less virulent pathogen. In assays utilizing various types of solid 
media, and particularly with Spider medium, a reduced ability to form lateral, invasive 
hyphae was shown repeatedly with the pldl~1 mutant. Unpublished data from our 
laboratory (Bell et at.; manuscript in preparation) have established C. albicans pld1Ll1 as 
an avirulent strain in a mouse model system. It was detennined that alimentary tract 
colonization was the same for strains B311 (wildtype, homozygous for URA3), CAF2-1 
(wild type, heterozygous for URA3), andpldldl (mutant, heterozygous for URA3). 
However, when lethality experiments were perfonned, it was shown that at all time 
points up to 35-42 days,pldl~1-inoculated mice had a 100% survival rate in comparison 
to both wildtype strains, which demonstrated a 0% survival rate. Although it remains 
unclear exactly what role PLD 1 and its products play in the signaling pathway leading to 
morphogenesis, it is clear that a role for this enzyme does exist. 
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